Xeltis

Executive Summary

Xeltis is a Dutch medical device company pioneering restorative cardiovascular implants through its proprietary Endogenous Tissue Restoration (ETR) platform. The company's implants are designed to be gradually replaced by the patient's own living tissue, potentially reducing complications such as thrombosis, stenosis, and infection compared to conventional synthetic grafts. Xeltis is initially targeting two high-need indications: vascular access for hemodialysis and coronary artery bypass grafting (CABG). The ETR technology utilizes a unique polymer that degrades over time, allowing native tissue to infiltrate and remodel the implant, ultimately restoring a living, self-repairing vessel. This approach could improve long-term patency and reduce reintervention rates. Xeltis has reported positive early clinical data, including promising results in its first-in-human studies for dialysis access grafts. The company is planning pivotal studies to support regulatory submissions in Europe and the U.S. Given the aging population and growing prevalence of end-stage renal disease and coronary artery disease, Xeltis addresses a large market opportunity with a differentiated technology. However, the company faces competition from established graft manufacturers and emerging regenerative medicine players. Successful clinical outcomes and regulatory approvals would position Xeltis as a leader in the regenerative cardiovascular space. The company's progress is closely watched by investors interested in next-generation implants that offer a permanent, living solution.

Upcoming Catalysts (preview)

• Q2 2026Pivotal trial initiation for dialysis access graft80% success
• Q4 2026Interim data from coronary artery bypass graft study60% success
• H1 2027Regulatory filing for CE mark in Europe65% success